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Oxidative phosphorylation is an indispensable resource of ATP in tissues with high requirement of energy. If the ATP demand is
not met, studies suggest that this will lead to senescence and cell death in the aﬀected tissue. The term reserve respiratory capacity
or spare respiratory capacity is used to describe the amount of extra ATP that can be produced by oxidative phosphorylation in
case of a sudden increase in energy demand. Depletion of the reserve respiratory capacity has been related to a range of pathologies
aﬀecting high energy requiring tissues. During aging of an organism, and as a result of mitochondrial dysfunctions, the eﬃciency of
oxidative phosphorylation declines. Based on examples from the energy requiring tissues such as brain, heart, and skeletal muscle,
we propose that the age-related decline of oxidative phosphorylation decreases the reserve respiratory capacity of the aﬀected
tissue, sensitizes the cells to surges in ATP demand, and increases the risk of resulting pathologies.
1. Introduction
In aerobic cells the majority of ATP is produced by oxidative
phosphorylation. This process takes place in the mitochon-
dria where electrons that are donated from the Krebs cycle
are passed through the four complexes (complex I–IV)
comprising the electron transport chain (ETC), eventually
reducing oxygen and producing water. The flux of electrons
creates an electrochemical potential between the inter-
membrane space and the matrix of the mitochondria. This
potential is utilized by the ATP synthase to phosphorylate
ADP producing ATP.
Many cells operate at a basal level that only requires a part
of their total bioenergetic capability. The diﬀerence between
ATP produced by oxidative phosphorylation at basal and that
at maximal activity is termed “spare respiratory capacity” or
“reserve respiratory capacity”, where the latter denomination
will be used throughout this review. Under certain conditions
a tissue can require a sudden burst of additional cellular
energy in response to stress or increased workload. If the
reserve respiratory capacity of the cells is not suﬃcient to
provide the required ATP aﬀected cells risk being driven
into senescence or cell death. Exhaustion of the reserve
respiratory capacity has been correlated with a variety of
pathologies including heart diseases [1], neurodegenerative
disorders [2, 3], and cell death in smooth muscle [4].
According to the mitochondrial theory of aging, func-
tional alterations in mitochondria contribute to the aging
process [5]. The mitochondrion is the only organelle in ani-
mal cells that has a distinct genome and even though mito-
chondria are involved in metabolism of fatty acids, amino
acids, and lipids, initiation of apoptosis, and other essen-
tial cellular functions, the human mitochondrial genome
exclusively encodes 24 peptides needed for mitochondrial
protein synthesis and 13 essential subunits of the ETC and
ATP synthase. The encoded polypeptides comprise few but
essential subunits of complex I (7 peptides), complex III
(1 peptide), complex IV (3 peptides), and ATP synthase
(2 peptides) [6, 7]. It has been demonstrated that brain,
heart, and skeletal muscle of aging humans harbor an
increased mutational load of the mitochondrial genome
when compared to corresponding tissues of young [8–10].
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Mutations inmtDNA aﬀect the function of the ETC, the elec-
trochemical potential, and the generation of ATP by oxidative
phosphorylation. Furthermore, mutations of mtDNA can
result in an elevated production of reactive oxygen species
(ROS). ROS serve as second messenger molecules but an
overproduction can, as we have reviewed earlier [11], lead to
unwanted oxidation of lipids, proteins, and DNA which can
further lead to cellular damage, mutations, and cell death.
ROS generated by mitochondria have, therefore, numerous
times been appointed as the mediator of the mitochondrial
contribution to the aging process [12–14]. Even though this
relationship in some contexts has been validated, studies have
demonstrated that mitochondrial generated ROS cannot
be the sole explanation for the correlation between aging
and mitochondria. A strong relation between the fitness of
the mtDNA, premature aging, and age-related pathologies
has been demonstrated with the independent construction
of two mouse lines expressing mutated versions of the
mitochondrial polymerase gamma [15, 16]. Both mouse
lines developed an mtDNA mutator phenotype, which was
associated with a decreased oxidative phosphorylation but
neither displayed an increase in ROS production. Neverthe-
less, the two mouse lines displayed symptoms of premature
aging and reduced lifespan in the form of weight loss,
alopecia, osteoporosis, kyphosis, cardiomyopathy, anemia,
gonadal atrophy, and sarcopenia. The median lifespan was
reduced to 48 weeks and maximum lifespan of 61 weeks
when compared to the typical wildtype lifespan of 2 years
[15, 16]. In human fibroblasts and human endothelial cells
it has been demonstrated that chronic exposure to agents
uncoupling the mitochondrial membrane potential forces
the cells into premature senescence [17, 18]. Treating the cells
with an antioxidant eliminated increased ROS production
but did not prevent premature senescence [17, 19]. Rather
the premature senescence was found to be the result of a
decrease in the level of oxidative phosphorylation [19].
In this paper we hypothesize that mitochondria con-
tributes to aging and age-related pathologies through a life-
long continued decrease of the respiratory reserve capacity.
The decrease sensitizes high energy requiring tissues to an
exhaustion of the reserve respiratory capacity. This increases
the risk of a range of pathologies that correspondingly are
known to be age-related. Through a review of the eﬀects
of aging on the regulation of oxidative phosphorylation,
we wish to substantiate this hypothesis. In addition, by
using brain, heart, and skeletal muscle as examples, we will
review how an age-related decrease of the reserve respiratory
capacity is implicated in a variety of pathologies in the
aﬀected tissues.
2. Regulation of Reserve Respiratory Capacity
The energy requirement of diﬀerent tissues and cells fluctu-
ates constantly and the metabolism of ATP is correspond-
ingly regulated to avoid futile energy expenditure and to cater
the specific needs of diﬀerent tissues. In accordance, it has for
almost 60 years been known that the rate of mitochondrial
respiration increases when mitochondria synthesize more
ATP implying a feedback mechanism linking cellular ATP
demand to regulation of oxidative phosphorylation [20].
Today this feedback mechanism is better described, and it is
demonstrated to contain regulatory components that can be
divided into short- and long-term regulators.
Short-term regulators of the oxidative phosphorylation
exert their control in response to sudden changes of ATP
demand. Cytochrome c oxidase (Complex IV of the ETC) has
been demonstrated to be a potent facilitator of short-term
regulation [21]. Complex IV is the final electron acceptor
of the ETC and catalyzes the reduction of O2 to H2O.
The complex has been demonstrated to be allosterically
inhibited by ATP whereby a futile overproduction of ATP
is avoided [22, 23]. Furthermore, the catalytic activity of
complex IV is regulated by the mitochondrial electric mem-
brane potential [24, 25], balancing the activity of the ETC
according to the needs, while avoiding a hyperpolarization
of the mitochondrial membrane and, thereby, avoiding an
excessive ROS production [23]. Finally, nitric oxide (NO)
has at submicromolar concentrations been demonstrated to
act as a competitive inhibitor of complex IV and inhibit
electron transport at complex III [26–28]. Mitochondrial
NO is produced via the mitochondrial nitric oxide synthase
(mtNOS), which is located in the inner mitochondrial
membrane [29]. MtNOS physically interacts with both
complexes I and IV [30, 31]. It is generally believed that
mtNOS is a voltage-dependent enzyme whose generation
of NO is regulated by mitochondrial membrane potential
according to the energy requirement of the cell which in
turn regulates the activity of the ETC [32, 33]. Several other
targets exist for posttranslational regulation of the ETC and
the ATP synthase. Multiple phosphorylation sites have been
demonstrated in complex IV [34–36] and phosphorylation
of these sites has been shown to almost completely inhibit
the catalytic activity of the complex [35]. Similarly, complex
I and the ATP synthase have been demonstrated to contain
phosphorylation sites [37, 38]. The mtNOS is similarly post-
transcriptionally regulated by both acylation and phospho-
rylation [39].
Long-term regulators of the oxidative phosphorylation
are eﬀectors that alter the mitochondrial respiration in
response to a changing role for the mitochondria in the
tissue, for example, in skeletal muscles after endurance
training [40] or as demonstrated as a consequence of caloric
restriction [41]. Interestingly, caloric restriction has in the
cerebella of mice been correlated with an increased reserve
respiratory capacity [42]. This increase is proposed to be the
result of an enhanced expression of the nuclear nitric oxide
synthase (nNOS) and increased levels of nuclear NO which,
in contrast to mitochondrial produced NO, is proposed to
increase respiratory capacity by aﬀecting the transcriptional
coactivator PGC-1α [42]. Together with PGC-1β, PGC-1α
is known to be involved in regulation of mitochondrial
biogenesis [43].
Long-term regulators can also permanently change the
properties of the mitochondrial respiration. This allows a
diﬀerentiation of mitochondria making them specialized for
diﬀerent cells and tissues. Accordingly, the ratio between pro-
duced ATP and consumed oxygen can vary greatly between
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diﬀerent tissues. Heart and brain mitochondria of rats have
been demonstrated to produce ATP faster thanmitochondria
of the liver while liver mitochondria produce ATP more
eﬃciently using less oxygen per produced ATP [44]. This is
believed to be due to the expression of diﬀerent isoforms of
specific subunits of the ETC. Such isoforms are known for
cytochrome c of the ETC and complex IV. Accordingly it has
been found that cytochrome c is expressed as a somatic and
a testes-specific isoform in most mammals [45]. Complex
IV isolated from cow lung additionally showed a 2.5-fold
increased activity compared to liver complex IV [46]. It
has further been demonstrated that diﬀerent isoforms of
complex IV can explain diﬀerences in kinetic behavior of the
enzyme in mouse cortical astrocytes and cerebellar granule
cells [47].
By definition, the reserve respiratory capacity is the dif-
ference between ATP produced by oxidative phosphorylation
at basal and at maximal respiratory activity. Regulation of the
oxidative phosphorylation is divided into short- and long-
term regulators. Short-term regulators mediate the oxidative
phosphorylation according to the immediate energy require-
ment. Short-term regulators are, therefore, important for the
regulation of the basal activity of ATP production. Long-
term regulators of the oxidative phosphorylation modulate
the properties of the oxidative phosphorylation and are
correspondingly essential for the setting of the maximal res-
piratory capacity. In extension of this, the reserve respiratory
capacity is defined by the interplay between the short- and
long-term regulators of the oxidative phosphorylation.
3. Aging and Oxidative Phosphorylation
Aging impairs mitochondrial function by aﬀecting both
the capacity and the control of oxidative phosphorylation.
Reduced activities of complexes I and IV, but not complexes
II and III, have been found in aging mice and rats. In
brain tissue of aging rats a 22–35% reduction of com-
plex IV activity was measured [48]. A similar trend has
been demonstrated in humans where a reduced activity
of complex IV has been found in skeletal muscle, heart,
and brain of aging subjects [49–52]. Correspondingly, an
age-related decline of mitochondrial capacity for oxidative
phosphorylation has been demonstrated in both human
skeletal muscle and rat hearts [9, 52, 53]. One factor aﬀecting
oxidative phosphorylation is an age-related accumulation
of mtDNA mutations resulting in an aberrant expression
of mitochondrial encoded ETC subunits [9, 52]. Increas-
ing evidence suggests an important role of accumulating
mtDNA mutations in the pathogenesis of many age-related
neurodegenerative diseases as well as a number of age-
related pathological alterations of heart, skeletal muscle, and
the vascular system [54–56]. MtDNA is more susceptible
to DNA damages in comparison to nuclear DNA [57].
mtDNA molecules are localized in close proximity to the
ETC, which continuously generates ROS. Thus, the mutation
rate of mtDNA has been reported to be up to 15-fold
higher than that observed for nuclear DNA in response
to DNA damaging agents [57]. Cumulative damage to the
mtDNA is however, not the only contributor to the age-
related decline of oxidative phosphorylation. Transcriptional
profiling has revealed diﬀerent regulation of nuclear genes
encoding important peptides for oxidative phosphorylation
when comparing young to old. In human frontal cortex the
α-subunit of the ATP synthase was found to be significantly
downregulated in old when compared to young [58]. Using
siRNA to approximate same expression levels of α-subunit
of the ATP synthase in a neuroblastoma cell line resulted
in a 24% reduction in cellular ATP levels [58]. In another
study, skeletal muscle from aging rhesus monkeys displayed
a selective down-regulation of nuclear-encoded proteins
involved in mitochondrial electron transport and oxidative
phosphorylation [59]. These included subunits of complex
I, complex IV, and ATP synthase. One mechanism that has
been proposed to link aging with decreased transcription
of nuclear genes encoding mitochondrial peptides is the
shortening of telomeres [60]. Telomerase deficient mice
were intercrossed to produce successive generations with
decreasing telomere reserves. The shortened telomeres of
subsequent generations were demonstrated to be associ-
ated with reduced mtDNA content and impaired oxidative
phosphorylation in the hematopoietic stem cells, livers,
and hearts of the telomerase deficient mice [60]. The
telomere dysfunction was associated with a repression of
the transcriptional coactivators PGC-1α and PGC-1β, and
this repression was hypothesized to be responsible for the
observed decline in mitochondrial function [60].
An age-related decline of oxidative phosphorylation can
therefore be related to a decline in expression of both
mitochondrial and nuclear expressed peptides functioning
in the ETC. This decline aﬀects most components of the
oxidative phosphorylation. Of the aﬀected components,
complex IV of the ETC stands out as it has an important
role in regulation of the oxidative phosphorylation. Complex
IV is the primary target of regulation by both short-term
and long-term regulators, and the complex is therefore the
main determinant of the maximal, basal, and thereby also
the reserve respiratory capacity of mitochondria. Nuclear
encoded subunits of complex IV have been shown to be
downregulated in an age-related manner [59]. Of the 13
peptides constituting complex IV, three are mitochondrial
encoded [6, 7]. Consequently, an age-related decline of
mtDNA fidelity also impairs the activity and the regula-
tory properties of complex IV and subsequently impairs,
or inactivates the ETC in all of the tissues reviewed in
this paper.
4. Reserve Respiratory Capacity in
Neuronal Diseases
Neurodegenerative diseases including Alzheimer’s disease,
Parkinson’s disease andHuntington’s disease, all have amajor
impact on personal lives as well as the society.
As reviewed by several, the mitochondrial function is
recognized as a causal factor in the pathogenesis of several
neuronal diseases [61–63]. The oxidative phosphorylation
and, thereby, respiratory capacity is critical for neuronal
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susceptibility to cellular stress caused by hypoxia, nutrients
depletion, or excitatory stimuli by neurotransmitters [64,
65]. The dependency of the human brain on oxygen for
oxidative phosphorylation is emphasized by the fact that the
human brain consumes approximately 16% of all oxygen
absorbed, but only accounts for 2% of the entire body mass
[66]. Furthermore, exhausting the reserve respiratory capac-
ity of a neuron can have fatal consequences. Resting neurons
utilize approximately 6% of its maximal respiratory capacity,
while firing neurons utilize up to 80% [67]. Therefore, subtle
decreases in reserve respiratory capacity from aging increase
neuronal vulnerability towards bioenergetic exhaustion, pre-
disposing the tissue for diseases. This is especially evident in
situations where the activity of complexes I and IV is reduced
[2, 68].
Rodent models of the neurodegenerative Alzheimer’s
disease shows that deficiency in mitochondrial respiration
precedes the pathology of the disease [69]. Alzheimer’s
disease is also accompanied by decreased expression and
activity of enzymes involved in mitochondrial bioenergetics,
as well as a generalized shift towards ketone bodymetabolism
[70]. Correspondingly, a decline of brain metabolism is
detectable in Alzheimer’s disease patients as early as a decade
before diagnosis [66].
Substantiating the importance of reserve respiratory
capacity in neuronal pathologies, evidence for a common
underlying mechanism reviewed by Nicholls and Budd in
2000 [71] and Rasola and Bernardi in 2011 [72] con-
nects the pathogenesis of ischemic reperfusion injury and
neurodegenerative diseases. This mechanism is initiated by
the depletion of ATP, a result of ischemic conditions or
perturbated reserve respiratory capacity [64], as reviewed by
Fiskum et al. in 1999 [65].
5. Neurons and Aging
The greatest risk factor in the course of neurodegenerative
diseases is advancing age as reviewed by Wallace et al. 1995,
Beal 1995, and Bishop et al. 2010 [61, 63, 73]. Mitochondrial
deletions and point mutations have been demonstrated to
accumulate in neuronal tissue with normal aging [74, 75].
Studies of age-related accumulation of oxidative damage
to both nDNA and mtDNA showed a preference for
accumulation of damages in mtDNA with increasing age,
aﬀecting components of the oxidative phosphorylation [76].
Therefore, mutations and deletions in mtDNA have been
suggested to be responsible for the aging-related factor in
some neurodegenerative diseases [61, 62, 77–79].
These studies support a lately revived hypothesis—that
neuronal cell death, in this context, primarily is induced
by an energy crisis as ATP demands exceed the maximal
respiratory capacity [80].
As reviewed by Lin and Beal in 2006 [79], a common
factor in sporadic and genetically predisposed neurodegener-
ative diseases is the gradual perturbation of the ETC resulting
in decreased activity of the oxidative phosphorylation and
hence, the maximal respiration. As aging has been correlated
to this, it therefore sensitizes neurons towards acute and
chronic stress, lowering the threshold for the amount of
damage the tissue can endure.
6. Reserve Respiratory Capacity in
Heart Disease
By using a surgical intervention of the heart known as an
aortic banding, it is possible to induce a pressure overload
resulting in acute and chronic stress of the cardiac tissue.
In pigs, aortic banding induces a condition mimicking
hypertrophy. When investigating the resulting hypertrophic
hearts in vivo, the reserve respiratory capacity was demon-
strated to be completely exhausted [81]. Similar results were
obtained from cardiac muscle tissue of rats [82–84] and in
cardiomyocytes treated with oxidized lipids [4]. The loss
of reserve respiratory capacity led to cell death or organ
dysfunction in the studied subjects.
Themechanism behind this fatal bioenergetic exhaustion
is not fully elucidated. Decreased expression and activity of
complex I and complex IV have been reported in hyper-
trophic cardiomyopathy and murine hearts with myocardial
infarct, suggesting impaired ETC [82, 83, 85–87], and a
possible cause to the reduced reserve respiratory capacity
observed in the failing heart. Even though reductions of
ETC activity have been found to cooccur with large-
scale deletions in mtDNA [87, 88], the inflicted cells only
constitute a fraction of the tissue. The impairment of the
ETC is, therefore, generally not believed to be caused by
a change in mtDNA content or quality [82, 88]. Rather
it has been proposed that the mitochondrial transcription
factor A (TFAM) and the corresponding nuclear respiratory
factor 2 (NRF-2) are downregulated resulting in a decreased
transcription of mitochondrial DNA [82, 84]. TFAM and
NRF-2 are downstream targets of the transcriptional coac-
tivator PGC-1α. Accordingly, polymorphisms of PGC-1α
have been correlated with an increased risk of hypertrophic
cardiomyopathy [89]. Furthermore, knockout of PGC-1α in
mice leads to decreased expression of ETC genes in the heart
and demonstrates a gene regulatory pattern comparable
to mice with hypertrophy following aortic constriction
[90]. Even though a downregulation of PGC-1α partly can
explain the demonstrated impaired ETC in the diseased
heart, mitochondrial dysfunction has been demonstrated
in hypertrophied hearts without a corresponding down-
regulation of PGC-1α [84]. In these cases a significant
downregulation of PPARα was demonstrated [84]. PPARα is
the key transcription factor for fatty acid oxidation.
A common feature of heart diseases is an inhibition of the
ETC resulting in a decreased activity of the oxidative phos-
phorylation and of the maximal respiration. This response is
not the consequence of mtDNA deterioration, but rather a
reduced transcription of mtDNA encoded genes. Where an
understanding of the pathway regulating this mechanism is
emerging, the benefits of such a response remains unclear.
Maybe it is an attempt to avoid the production of ROS as
demonstrated during ischemia [91].
No matter what the purpose, acute and chronic stress
in cardiac tissue inhibits the ETC and decreases reserve
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respiratory capacity of the tissue. The lowered capacitymakes
the heart more vulnerable to a bioenergetic exhaustion and
thereby increases the risk of inducing cell death and organ
failure. Aging has been demonstrated to reduce the fidelity
of myocardial mtDNA resulting in a reduction of maximal
respiratory capacity. Aging therefore further sensitizes the
heart to acute and chronic stress, lowering the threshold of
damage a heart can endure.
7. Skeletal Muscle and Aging
The progressive loss of skeletal muscle mass and strength
observed in older individuals is a condition known as
sarcopenia. The condition has been correlated with aging as
well as mitochondrial dysfunction [92]. The mitochondrial
reserve capacity is essential for skeletal muscle, and it
has been demonstrated that an exhaustion of the reserve
respiratory capacity, induced by diamides, causes cell death
in vascular smoothmuscle of rats [4]. Similarly, proofreading
deficient polymerase gamma mice has been used to model
mitochondrial related sarcopenia. The mice developed an
mtDNA mutator phenotype and several signs of premature
aging, including a significant loss of skeletal muscle. The
study demonstrated an increased spontaneous mutation rate
in the mtDNA correlated with a 35–50% reduction in the
content of complex I, III, and IV, a decrease of oxidative
phosphorylation and, thereby, a lower ATP content and
reserve respiratory capacity [93]. The decrease of oxidative
phosphorylation ultimately resulted in an induction of
apoptosis in the tissue and finally sarcopenia allowing the
authors to conclude that mtDNAmutations can have a causal
role in sarcopenia [93].
Several large-scale studies on skeletal muscle biopsies
from humans of ages ranging from 17 to 91 years have shown
a significant age-related decline in mitochondrial respiratory
capacity [52, 94, 95]. One study demonstrated a 50%
downregulation of mitochondrial oxygen capacity in elderly
compared to adult skeletal muscle [94]. The reduced capacity
of oxidative phosphorylation can partly be explained by
an increase in mtDNA mutations and a significant down-
regulation of subunits of complex I and IV demonstrated
in the aging skeletal muscle of humans [9, 96–99]. It has
been proposed that the aging muscle compensates for the
lower mitochondrial respiratory capacity by upregulation
of the mitochondrial content to avoid rate-limiting ATP
production [99]. Accordingly, ragged red fibers harboring an
abnormal accumulation of mitochondria have been shown
to occur in aging skeletal muscle [100]. The occurrence
of ragged red fibers was investigated in biopsies of skeletal
muscle obtained from humans at various ages. Ragged red
fibers were demonstrated to be extremely rare in subjects
under the age of 40 years, while they were demonstrated in
more than half of the subjects between the age of 40 and
50 years, and in almost all of the subjects older than the age
of 50 years [100]. The biopsies were stained for complex IV
activity and it was demonstrated that in subjects under the
age of 40 years, none, except an outlier, presented complex IV
negative fibers. In subjects between the age of 40 and 50 years
only 21% carried complex IV negative fibers, and almost
all subjects above the age of 50 years displayed complex
IV negative fibers [100]. This indicates that even though
the cells attempt to compensate for a low mitochondrial
respiratory capacity by upregulating mitochondrial content,
this is only possible until the age of 50 as demonstrated by
the occurrence of complex IV negative fibers.
The complex IV negative fibers were demonstrated to be
associated with a decrease of mtDNA content [100]. This
was also shown in a separate study where mtDNA content
of human skeletal muscle was demonstrated to decrease
in an age-related fashion. This study also determined an
age-related decrease of both nuclear and mitochondrial
expression of genes encoding subunits of complex IV and
this decrease was correlated with a corresponding decrease
of mitochondrial ATP production rate. Together this led the
authors to suggest that the declining mitochondrial function
could contribute to the low physical function that is common
in older people [9].
8. Skeletal Muscle and Physical Activity
Increasing evidence shows that the age-related loss of muscle
strength can be avoided, or the muscle strength can be
regained by regular endurance exercise [97, 101]. Several
studies have investigated the eﬀect of exercise on the mito-
chondrial metabolism in aging. It has been demonstrated
that the mitochondrial ATP production rate in skeletal
muscle was significantly lowered with age in groups having
a sedentary lifestyle compared to groups with an active
lifestyle. Interestingly, no diﬀerence in reserve respiratory
capacity was observed between young and old in the active
group [97, 102]. Studies on skeletal muscle biopsies from
healthy young (age 18–43 years) and older (aged 59–76)
have shown that there is an age-related decline in mtDNA
content [97, 101, 103]. However, the mtDNA levels of groups
leading an active lifestyle were significantly higher compared
to the inactive, even though the age-related decline still
persisted [97, 101]. Furthermore, the ADP and inorganic
phosphate substrate concentrations of the ATP synthase has
been shown to be significantly higher in inactive individuals
compared to active as well as in elderly compared to young
indicating an age-related and sedentary lifestyle associated
decrease in ATP synthase activity [95, 102]. Another study of
the relative abundance of proteins involved in key metabolic
processes in human skeletal muscle revealed a significant
age-related decline in 16 proteins involved in the oxidative
phosphorylation in the inactive persons. In the active group
only subunits of complex IV and an aminotransferase were
less abundant in old compared to young [97]. An immediate
eﬀect of physical exercise has also been shown. Eight healthy
elderly men and women with a sedentary lifestyle were
subjected to a 12 week exercise training program. The
investigation showed a 53% increase in skeletal muscle
mtDNA content after the 12 week program, as well as an
almost doubling of ETC activity from complex I through
IV and a 62% increase of ETC activity from complex II
through IV. The investigations show that a sedentary lifestyle
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can cause sarcopenia. However, the age-related decline in
respiratory capacity can be avoided or reversed by regular
endurance exercise [101].
9. Conclusion
Generation of ATP by mitochondrial respiration is in many
tissues an indispensible source of energy. Many cells and
tissues operate at a basal level that only requires a part of their
total bioenergetic capability, allowing a reserve respiratory
capacity for sudden surges in energy requirement. If the
energy requirement supersedes what the reserve respiratory
capacity can provide, the cell and the aﬀected tissue risk
cell death and organ failure. A decline of the reserve
respiratory capacity can increase the incidence of a range
of pathologies normally associated with aging. As reviewed,
this is evidenced in mouse models having a higher mtDNA
mutation rate [15, 16, 93] and in inherited mitochondrial
diseases [8]. Mutations of the mtDNA exclusively aﬀect the
components of the ETC and the ATP synthase. As described
in this paper a disruption of both the control and eﬃciency
of especially complex IV has a significant eﬀect on the short-
and long-term regulators of the oxidative phosphorylation,
and in extension, the reserve respiratory capacity.
Aging aﬀects most components of the oxidative phos-
phorylation, which is mediated both by an age-related
decline of mtDNA and an age-related decreased expression
of nuclear encoded subunits. Of the two genomes, mtDNA
has been demonstrated to be most susceptible to age-related
accumulation of mutations and deletions [57]. As a result,
tissues including brain, heart, and skeletal muscle are subject
to an age-related deterioration with a cooccurring loss of
both activity and control of the oxidative phosphorylation.
Neuronal tissue is a tissue that is highly dependent of
oxidative phosphorylation. This is evidenced by the fact that
neurons are demonstrated to use up to 80% of maximal
respiratory capacity when firing [67]. In heart tissue, the
reserve respiratory capacity plays a pivotal role during acute
and chronic stress of the heart. A variety of heart condi-
tions were demonstrated to exhaust the reserve respiratory
capacity, leading to cell death when depleted [4, 81–84]. In
skeletal muscle, loss of reserve respiratory capacity has been
directly related to sarcopenia [93]. With an age-related loss
of both activity and control of the oxidative phosphorylation
the maximal respiratory capacity will decrease in an age-
related manner. This lowers the reserve respiratory capacity
of the aﬀected tissues and sensitizes them to sudden surges of
ATP demand. As a result the risk of a number of pathologies
manifesting in the tissue will be increased.
In the three long-lived postmitotic cell types described
in this paper, neurons, heart cells and skeletal muscle cells,
cell death, and senescence can be caused by an exhaustion
of the reserve respiratory capacity due to mitochondrial
dysfunction or aging. This can result in organ failure and
have fatal consequences. In contrast to heart and brain, an
age-related decline of oxidative phosphorylation has been
demonstrated to be reversible in skeletal muscle [101]. An
attractive explanation to this could be that skeletal muscles
can be regenerated from adult stem cells containing intact
mitochondria to a larger extent than what is possible for
brain and neurons.
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